The Food and Drug Administration has finalized three guidance documents telling cancer trial sponsors to stop carrying over eligibility restrictions that were never scientifically justified for the specific study being run.
The three documents, posted together on July 27, cover laboratory value thresholds, performance status, and washout periods with concomitant medication rules. Each finalizes a draft first issued in April 2024. Together they represent the agency's clearest statement yet that the standard exclusion criteria copied from one oncology protocol into the next are themselves a problem worth regulating.
The stake for patients is access. The FDA's Oncology Center of Excellence noted that fewer than 5 percent of cancer patients currently in treatment are enrolled in a clinical trial, while more than 70 percent say they would be willing to participate, according to reporting by the Regulatory Affairs Professionals Society. The guidance names overly stringent eligibility criteria as one reason for that gap.
Three Documents Aimed at One Habit
The agency's framing is consistent across all three. Eligibility criteria exist to select the intended patient population and reduce risk to participants. The problem, FDA says, is that some criteria became commonly accepted over time and are now used as a template across trials without being reconsidered for the study at hand.
In the notice announcing the laboratory values guidance, the agency wrote that "unnecessarily restrictive eligibility criteria may slow patient accrual, limit patients' access to clinical trials," and produce results that do not fully represent how a drug will perform in the population that eventually uses it.
The laboratory values document asks sponsors to set thresholds based on the investigational drug's mechanism of action, its pharmacokinetic and pharmacodynamic profile, anticipated toxicities and available clinical data, rather than on convention. It also recommends repeat testing when a single abnormal value may not be clinically meaningful, and asks sponsors to revisit exclusions as safety data accumulates during development.
The performance status guidance addresses the functional scoring systems that determine whether a patient is considered well enough to enroll. FDA recommends expanding criteria to include a wider range of performance status, and the final version adds discussion of how doing so affects trial retention and sample size.
The washout and concomitant medications guidance tackles the waiting period between stopping a prior cancer drug and starting an experimental one, along with rules barring patients on certain other medications. FDA noted that these exclusions vary widely across trials for similar drug classes and diseases without a clear rationale.
Lab Numbers That Quietly Decide Who Gets a Seat
Most patients never see the eligibility criteria that ruled them out. A screening result comes back, and the trial coordinator says the patient does not qualify.
Laboratory thresholds are among the most common reasons. A kidney function value slightly below a protocol cutoff, a platelet count under a fixed floor, a liver enzyme modestly elevated, or a hemoglobin level below a number chosen years earlier for a different drug can all end a screening.
Those cutoffs matter clinically because the patients they exclude are often the patients who most closely resemble real oncology practice. Older adults, people with reduced kidney function, patients with prior treatment that suppressed blood counts, and people managing more than one chronic condition are disproportionately screened out. When a drug is later approved, clinicians treat exactly those patients with data that never included them.
The FDA's Oncology Center of Excellence said the July documents "address one reason for this low participation rate," pointing to stringent and complex criteria.
Limits of What a Guidance Can Actually Change
This is a regulatory shift, not a treatment advance. It changes nothing about how any cancer is treated today, and it does not open any specific trial to any specific patient.
FDA guidances are not binding. Each document states explicitly that it represents the agency's current thinking, does not establish rights for any person, and that sponsors may use an alternative approach that satisfies applicable statutes and regulations. Whether trial protocols actually loosen depends on decisions made by drug sponsors, institutional review boards, and individual trial sites.
The changes from draft to final were modest. FDA described the laboratory values and washout revisions as minor clarifications, and the performance status revisions as added considerations for sponsors plus clarity edits. Comments received on the 2024 drafts were considered in finalizing.
There is also no published evidence yet showing that this series of guidances has increased enrollment. FDA has issued similar eligibility documents since 2020 covering brain metastases, pediatric age minimums, patients with HIV or viral hepatitis, and patients with organ dysfunction or prior malignancies. Measuring their cumulative effect on accrual will take years of protocol data.
Questions Worth Bringing to an Oncology Appointment
Patients and families should not read this as a signal to seek out experimental therapy. It is a signal that a previous rejection may be worth revisiting.
Someone who was screened out of a trial on a laboratory value, a performance status score or a washout requirement can reasonably ask their oncologist whether the protocol has been amended, whether a repeat test might now fall within range, and whether a similar trial at another site uses different criteria. Patients whose tumor has not undergone molecular profiling can ask whether that testing has been done, since it determines eligibility for many targeted trials.
Caregivers should know that trial participation carries real costs and burdens, including travel, additional visits, and uncertainty about benefit. Broader eligibility is not the same as broader benefit, and nobody should stop or change an existing treatment in order to pursue a trial without discussing it with their oncology team.
FDA accepts comments on any guidance at any time through regulations.gov under the relevant docket numbers. The agency has said it updates these documents periodically. MedicalDaily will monitor whether additional guidances in this series are finalized and whether trial sponsors publicly revise protocols in response.
Frequently Asked Questions
What did the FDA actually issue? Three final guidance documents on cancer trial eligibility criteria, covering laboratory values, performance status, and washout periods with concomitant medications. All three finalize drafts from April 2024.
Does this change how cancer is treated? No. These documents address how clinical trials are designed. They do not change any approved treatment or clinical guideline.
Are sponsors required to follow the guidances? No. FDA guidances are non-binding and state the agency's current thinking. Sponsors may use an alternative approach that meets applicable law.
Who is most often excluded by these criteria? Patients with reduced kidney or liver function, low blood counts, lower functional status scores, or those taking medications that conflict with protocol restrictions. Older adults and people with multiple conditions are disproportionately affected.
Could a patient previously turned down now qualify? Possibly, if a sponsor amends the protocol. Patients can ask their oncologist whether criteria have changed or whether another site runs a comparable trial with different thresholds.
How many cancer patients enroll in trials? FDA's Oncology Center of Excellence cited enrollment below 5 percent among patients currently in treatment, against more than 70 percent expressing willingness to participate.
Where can the guidances be read? They are posted on the FDA guidance documents website and announced through the Federal Register under dockets FDA-2024-D-1402, FDA-2024-D-1377 and FDA-2024-D-1376.
